Company profile: InMed Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of cannabinoid-based pharmaceutical candidates and rare cannabinoid ingredients. Develops INM-755 (cannabinol topical for epidermolysis bullosa) and INM-088 (cannabinol-based for glaucoma). Through BayMedica, supplies bioidentical rare cannabinoids (CBC, d9-THCV, CBDV, CBTC) for B2B health and wellness. Offers IntegraSyn, combining biosynthesis and chemical synthesis to produce cannabinoids, aiming for high yield and cost efficiency.
Products and services
- BayMedica: A subsidiary produces bioidentical rare cannabinoids for B2B purchase, including CBC, d9-THCV, CBDV, and CBTC, for incorporation into health and wellness products
- INM-755: A topical cannabinol cream developed for epidermolysis bullosa that alleviates symptoms and manages complications in affected skin
- INM-088: A cannabinol-based formulation for glaucoma that reduces intraocular pressure and provides neuroprotection for optic nerve tissues, combining pressure-lowering and neuroprotective effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to InMed Pharmaceuticals
AstraZeneca
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical research, development, manufacturing, and marketing of prescription medicines across oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases. Portfolio includes therapies such as datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer, with clinical trial survival benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AstraZeneca company profile →
OncoZenge
HQ: Sweden
Website
- Description: Provider of supportive care products for cancer patients. Swedish pharmaceutical company developing BupiZenge™, a lozenge designed to provide local pain relief for oral mucositis, a common side effect of radiotherapy and chemotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoZenge company profile →
NewBiotics
HQ: United States
Website
- Description: Provider of drug discovery and development focused on molecules that leverage the cycle of drug resistance in cancer and infectious diseases, transforming drug resistances into therapeutic advantages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NewBiotics company profile →
Genzyme
HQ: United States
Website
- Description: Provider of biotechnology products and services focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune disease, operating across four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery, and Hematologic Oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genzyme company profile →
Corridor Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform-based pulmonary and critical care therapeutics, developing and commercializing small-molecule inhibitors of arginase to address elevated arginase levels, targeting arginase—an enzyme that competes with endothelial nitric oxide synthase for l-arginine and leads to ornithine production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corridor Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for InMed Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to InMed Pharmaceuticals
2.2 - Growth funds investing in similar companies to InMed Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for InMed Pharmaceuticals
4.2 - Public trading comparable groups for InMed Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →